Browsing Tag
Akeso
7 posts
Summit Therapeutics launches global Phase III HARMONi-GI3 trial as ivonescimab enters colorectal cancer race
Find out how Summit Therapeutics and Akeso are betting on ivonescimab’s expansion into colorectal cancer and why investors see it as a defining moment for the biotech’s future.
Akeso completes patient enrollment for Phase III Cadonilimab trial in high-risk HCC
Akeso, Inc. has announced the completion of patient enrollment for its Phase III cadonilimab trial (COMPASSION-22/AK104-306), marking a…
New hope for asthma and eczema? Akeso’s latest antibody AK139 enters clinical trials
Akeso, Inc. (9926.HK) has announced a major milestone with the acceptance of its Investigational New Drug (IND) application…
Akeso begins Phase 3 trial of cadonilimab as consolidation therapy for non-small cell lung cancer
Akeso, Inc. (9926.HK) has initiated its pivotal Phase 3 cadonilimab trial for non-small cell lung cancer (NSCLC), marking…
Akeso advances cancer immunotherapy as Ivonescimab reaches Phase III milestone in lung cancer treatment
Akeso, Inc. (9926.HK) has completed patient enrollment for its pivotal Phase III trial (HARMONi-6), marking a significant step…
Akeso’s Gumokimab poised to redefine Psoriasis treatment
Akeso, Inc., a leading biopharmaceutical innovator based in Hong Kong, is making significant strides in the treatment of…
Chinese biopharma company Akeso raises $150m for antibody drug discovery
Akeso, a Chinese biopharma company engaged in antibody drug discovery and development in oncology and immunology therapeutic areas,…